Platelet-derived growth factor receptor-like protein (PDGFRL)

Platelet-derived growth factor receptor-like protein (PDGFRL) is a secreted glycoprotein comprised of two Ig-like C2-type domains, with significant sequence similarity to the ligand-binding domain of platelet-derived growth factor receptor beta, but no classical intracellular kinase activity[2][4][6]. PDGFRL is implicated as a tumor suppressor, with loss-of-function or gene deletions associated with various cancers[2][4][6][10]. Recent research identifies PDGFRL as a therapeutic target in osteoarthritis, where its expression is upregulated in diseased cartilage, and monoclonal antibody blockade preserves cartilage and modulates inflammatory cytokines[3]. PDGFRL also plays roles in chondrocyte proliferation and differentiation, and is involved in autoimmune diseases such as Behçet disease and rheumatoid arthritis, likely through immune regulatory pathways[4][6]. The exact molecular function and downstream signaling of PDGFRL remain incompletely understood[1][5].

Other names

PDGFRLPRLTSPDGFR-like proteinPDGF receptor beta-like tumor suppressorPlatelet-derived growth factor receptor-like proteinPlatelet-derived growth factor-beta-like tumor suppressorPDGRL

Monoclonal antibodies: Block PDGFRL activity, preserve cartilage integrity, and slow osteoarthritis progression Potential inhibition of cell clustering, ECM degradation, and apoptosis pathways in chondrocytes